# FDA 483 - Charles River Laboratories Inc - August 25, 2023

Source: https://www.globalkeysolutions.net/records/483/charles-river-laboratories-inc/b56b53e9-5822-4c90-a349-94e94e2c35a0

> FDA 483 for Charles River Laboratories Inc on August 25, 2023. Product: biologics. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Charles River Laboratories Inc
- Inspection Date: 2023-08-25
- Product Type: biologics
- Office Name: Division of Clinical Evidence and Analysis 1 (Clinical Policy and Quality)

## Related Documents

- [483 - 2024-10-11](https://www.globalkeysolutions.net/records/483/charles-river-laboratories-inc/97c49f67-f4f5-4f09-bfc2-3e3d25eb14fd)
- [483 - 2025-02-07](https://www.globalkeysolutions.net/records/483/charles-river-laboratories-inc/d2020951-fd3b-43e4-8e49-ee44f95bde21)
- [483 - 2025-02-07](https://www.globalkeysolutions.net/records/483/charles-river-laboratories-inc/9b011bb3-c734-4ee0-8977-38ba157887d6)
- [483 - Unknown Date](https://www.globalkeysolutions.net/records/483/charles-river-laboratories-inc/69211940-68d6-412b-ac3d-1bba673c4233)
- [EIR - Unknown Date](https://www.globalkeysolutions.net/records/eir/charles-river-laboratories-inc/3c98f1c8-a15e-4c80-9a50-fd3a7f95fcff)

## Related Officers

- [Hoda Abadeer](https://www.globalkeysolutions.net/people/hoda-abadeer/4ae6231f-1403-4d23-b551-e273a5de3c04)
- [Prajakta A. Varadkar](https://www.globalkeysolutions.net/people/prajakta-a-varadkar/93c01972-2e91-462e-8c2b-4a6520d3dd3f)
- [investigator](https://www.globalkeysolutions.net/people/wei-wang/943039ac-3917-4d32-9f58-1886c56aecdd)
- [Zhenzhen Ye](https://www.globalkeysolutions.net/people/zhenzhen-ye/a56d2d09-fbf3-4553-8c81-be3a372d76cb)
- [Jessica Chery](https://www.globalkeysolutions.net/people/jessica-chery/a7031c2d-307b-45b0-9078-0ce3f81dfc8a)

Company: https://www.globalkeysolutions.net/companies/charles-river-laboratories-inc/876b68d9-6285-4039-8732-05f876b5d911

Office: https://www.globalkeysolutions.net/offices/division-of-clinical-evidence-and-analysis-1-clinical-policy-and-quality/5f95da17-30bb-423f-b892-5ea041823fbd